Purpose: To perform a risk mitigation review of intravitreal injections. Methods: A pan-European expert team conducted a healthcare failure modes and effects analysis (HFMEA) of intravitreal injection techniques. Possible failures at each stage were identified and potential causes and effects considered. A risk value (1-10) was assigned for each failure's severity, probability of occurrence and likelihood of going undetected, and a risk priority number (RPN) calculated. Results: This HFMEA revealed 91 intravitreal injection failure modes, of which 28, deemed to have an appreciable risk, were explored. Recommendations were proposed to reduce these risks, mostly relating to patient, staff, room and equipment preparation, injection procedure and patient discharge. Conclusions: The HFMEA process produced practical recommendations to improve the risk profile of intravitreal injection.

Keywords:
Intravitreal injection, Healthcare failure modes and effects analysis, Guidelines, Risk, Failure modes, Adverse events
1.
Marticorena J, Romano V, Gómez-Ulla F: Sterile endophthalmitis after intravitreal injections. Mediators Inflamm 2012, DOI: 10.1155/2012/928123.
2.
Royal College of Ophthalmologists: Age-related macular degeneration guidelines for management. http://www.rcophth.ac.uk/page.asp?section=451 (accessed May 2013).
3.
Royal College of Ophthalmologists: Interim guidelines for management of retinal vein occlusion. http://www.rcophth.ac.uk/page.asp?section=451 (accessed May 2013).
4.
Wang D, Pan J, Avrunin G, Clarke LA, Osterweil LJ, Chen B: An automatic failure mode and effect analysis. Technique for processes defined in the Little-JIL process definition language. Proc Int Conf Software Eng Knowledge Eng, Redwood City, 2010, pp 765-770.
5.
Royal College of Ophthalmologists: Guidelines for intravitreal injections procedure. http://www.rcophth.ac.uk/page.asp?section=451 (accessed May 2013).
6.
Società Oftalmologica Italiana: LINEE GUIDA Iniezione di Farmaci per via Intravitreale (IVT). http://www.sedesoi.com/pdf/intravitreali_aggiornato.pdf (accessed May 2013).
7.
Gomez-Ulla F, Bassauri E, Arias L, Martinez-Sanz F: Management of intravitreal injections. Arch Soc Esp Oftamol 2009;84:377-388.
8.
Agence française de sécurité sanitaire des produits de santé: Bonnes pratiques d'injection intra-vitréenne (IVT). http://www.fnro.net/documents/Afssap/Afssap.html.
9.
Frenkel REP, Haji SA, La M, Frenkel MPC, Reyes A: A protocol for the retina surgeon's safe initial intravitreal injections. Clin Ophthalmol 2010;4:1279-1285.
10.
John B: Intravitreal injections. Kerala J Ophthalmol 2007;1:44-57.
11.
Doshi RR: Intravitreal injection technique. Semin Ophthalmol 2011;26:104-113.
12.
Korobelnik JF, Weber M, Cohen SY: Guidelines for intravitreal injections. J Fr Ophtalmol 2009;32:e1-e2.
13.
Royal College of Ophthalmologists: Ranibizumab: the clinician's guide to commencing, continuing and discontinuing treatment. http://www.rcophth.ac.uk/page.asp?section=451.
14.
United States Department of Veteran Affairs: HFMEA. http://www.patientsafety.gov/Cog Aids/HFMEA (accessed May 2013).
15.
Meyer CH, Fung A, Saxena S, Holz FG: Steps for a safe intravitreal injection technique. http://www.retinalphysician.com/articleviewer.aspx?articleid=103195 (accessed May 2013).
16.
Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I: Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781.
17.
Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat A-HS, Dellinger EP, Herbosa T, Joseph S, Kibatala PL, Lapitan MCM, Merry AF, Moorthy K, Reznick RK, Taylor B, Gawande AA, Safe Surgery Saves Lives Study Group: A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009;360:491-499.
18.
Chong V, Kaiser PK, Mitchel P: Safety and efficacy of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration. Eur Ophthalmic Rev 2012;6:34-41.
19.
Moshfeghi AA, Rosenfield PJ, Flynn HW, Schwartz SG, Davis JL, Murray TG, Smiddy WE, Berrocal AM, Dubovy SR, Lee W-H, Albini TA, Lalwani GA, Kovach JL, Puliafito CA: Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists. Retina 2011;31:662-668.
20.
McCanel CA: Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Retina 2011;31:654-661.
21.
Alwitry A, Jackson E, Chen H, Holden R: The use of surgical facemasks during cataract surgery: is it necessary? Br J Ophthalmol 2002;86:975-977.
22.
Gifford C, Christelis N, Cheng A: Preventing postoperative infection: the anaesthetist's role. Contin Educ Anaesth Crit Care Pain 2011;11:151-156.
23.
Romney MG: Surgical face masks in the operating theatre: re-examining the evidence. J Hosp Infect 2001;47:251-256.
24.
Stevens S, Cox I: Care of ophthalmic surgical instruments. Community Eye Health 2000;13:40-41.
25.
Aflibercept SmPC, December 2012. http://www.medicines.org.uk/emc/medicine/27224 (accessed May 2013).
26.
Ranibizumab SmPC, January 2012. http://www.ema.europa.eu (accessed May 2013).
27.
Saimen L, Siegel J: Infection control in cystic fibrosis. Clin Microbiol Rev 2004;17:57-71.
28.
Manchikanti L, Malla Y, Wargo BW, Fellows B: Infection control practices (safe injection and medication vial utilization) for interventional techniques: are they based on relative risk management or evidence? Pain Physician 2011;14:425-434.
29.
Fischer D, Pavlidis M, Thanos S: Cataractogenic lens injury prevents traumatic ganglion cell death and promotes axonal regeneration both in vivo and in culture. Invest Ophthalmol Vis Sci 2000;41:29433-3954.
30.
Lopez-Guajardo L, del Valle FG, Moreno JP, Teus MA: Reduction of pegaptanib loss during intravitreal delivery using an oblique injection technique. Eye 2008;22:430-433.
31.
Vaninbroukx I, Van Calster J, Van Calster B, Spileers W, Verhaegen J, Stalmans P: Preoperative eye disinfection in vitrectomy surgery using antibiotic or antiseptic eyedrops. Bull Soc Belge Ophtalmol 2010;315:9-12.
32.
Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics. Arch Ophthalmol 2011;129:1180-1111.
33.
Mokkink L, Terwee CB, Gibbons E, Stratford PW, Alonso J, Patrick DL, Knol DL, Bouter LM, de Vet HCW: Inter-rater agreement and reliability of the COSMIN (Consensus-based Standards for the Selection of Health Status Measurement Instruments) Checklist. BMC Med Res Methodol 2010;10:82.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.